Jacobs & Co. CA Has $4.36 Million Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Jacobs & Co. CA raised its stake in Kenvue Inc. (NYSE:KVUE) by 20.4% during the 4th quarter, Holdings Channel reports. The institutional investor owned 202,665 shares of the company’s stock after purchasing an additional 34,282 shares during the quarter. Jacobs & Co. CA’s holdings in Kenvue were worth $4,363,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. bought a new stake in shares of Kenvue during the 3rd quarter worth $2,944,816,000. FMR LLC boosted its holdings in shares of Kenvue by 572.1% during the 3rd quarter. FMR LLC now owns 89,182,980 shares of the company’s stock worth $1,790,794,000 after buying an additional 75,913,107 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Kenvue by 576.1% during the 3rd quarter. Wellington Management Group LLP now owns 71,686,830 shares of the company’s stock worth $1,439,472,000 after buying an additional 61,084,123 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in shares of Kenvue by 227.7% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 61,091,189 shares of the company’s stock worth $1,226,711,000 after buying an additional 42,449,470 shares during the period. Finally, Morgan Stanley boosted its holdings in shares of Kenvue by 4,057.4% during the 3rd quarter. Morgan Stanley now owns 31,162,614 shares of the company’s stock worth $625,745,000 after buying an additional 30,413,040 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Kenvue stock opened at $21.45 on Thursday. The company’s 50 day simple moving average is $20.00 and its 200 day simple moving average is $20.25. Kenvue Inc. has a fifty-two week low of $17.82 and a fifty-two week high of $27.80. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.12 and a quick ratio of 0.78.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.03. The business had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.78 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The business’s revenue was down 2.7% compared to the same quarter last year. As a group, equities analysts anticipate that Kenvue Inc. will post 1.17 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Tuesday, February 13th. This represents a $0.80 dividend on an annualized basis and a yield of 3.73%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on KVUE shares. UBS Group increased their price target on shares of Kenvue from $20.00 to $23.00 and gave the company a “neutral” rating in a report on Tuesday, December 19th. The Goldman Sachs Group assumed coverage on shares of Kenvue in a research note on Friday, March 1st. They issued a “neutral” rating and a $20.00 price objective for the company. JPMorgan Chase & Co. dropped their price objective on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 9th. Finally, Royal Bank of Canada dropped their target price on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Friday, February 9th. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $25.42.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands.